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lines mutated for the endogenous PTEN locus suffered deleterious effects on cell cycle progression (G1 arrest), proliferative capacity and survival when transfected with a wild type, but not a catalytically-inactive, form of the phosphatase, suggesting that the enzymatic activity of the enzyme was involved with the regulation of this phospholipid signaling [6] [16] [17] . These studies suggested that the loss of this phosphatase in tumors induced the upregulation of the AKT/PKB signaling pathway, which resulted in cell cycle progression and inhibition of apoptosis.
A number of animal model studies supported an important role for PTEN in the control of proliferation, survival and cell size. Importantly, mice with homozygous null mutations in the PTEN locus showed early embryonic lethality due to an apparent hyperproliferative effect, while heterozygous animals developed tumors postnatally with apparent loss of heterozygosity at the PTEN locus [18] [19] . This latter result suggested that the loss of PTEN expression was an advantageous event, which allowed tumors to grow in a more unregulated manner after the accumulation of other oncogenic mutations. Cell lines derived from PTEN null embryonic mice demonstrated higher levels of PIP 3 phospholipids and enhanced activation of the AKT/PKB kinase [19] . These cells also showed significant resistance to a diversity of apoptotic stimuli, further endorsing a role for this phosphatase in the regulation of cell survival through the PI3 kinase pathway. Additional evidence in both C. elegans and Drosophila supported a role for the PTEN phosphatase in the regulation of cell growth and survival. C. elegans contains an insulin-like pathway , including an insulin -like receptor tyrosine kinase, a PI 3 kinase, PDK and AKT/PKB kinases and a forkhead-like transcription factor, which is involved with dauer formation, a developmental stage where worms undergo a quiescent state. Genetic analysis of this pathway demonstrated that a worm homologue of PTEN, termed DAF 18, could suppress upstream mutations in either the insulin-like by guest on November 19, 2017 http://www.jbc.org/ Downloaded from 5 receptor or PI 3 kinase, completely consistent with results found in the mammalian PI 3 kinase pathway [20] . The involvement of this pathway in the regulation cell size was further suggested by studies in Drosophila. These data demonstrated that the fly homologue of PTEN was involved with the determination of cell size, consistent with other studies, which established the importance of several components of the PI 3-kinase pathway, such as AKT/PKB [21] [22] . Together, these three separate animal models provided strong proof for the relevance of the PTEN lipid phosphatase in the regulation of various aspects of the PI 3 kinase pathway.
X ray crystallographic analysis of PTEN structure revealed that this phosphatase contains a novel substrate recognition pocket with positively charged residues potentially involved with the association of the phosphates on the inositol ring substrate [12] . Positioning of many tumor derived mutations known to disrupt catalytic activity to the active site in part served to explain the mechanism of action of the phosphatase.
The mechanism by which PTEN appears to be associated with its phospholipid substrates appears to be quite complex. Structural analysis revealed a functional C2 lipid binding domain in the carboxy-terminal region of the protein, which was proposed to serve as a lipid association motif [12] . Many tumor-derived mutations have been mapped to the carboxy-terminus, and a fraction of these are involved with the formation of an interface between the phosphatase domain and the C2 domain. These latter results helped to explain why mutations in the carboxy-terminal region appeared to affect catalytic activity. Human, mouse and Drosophila PTEN all contain a PDZ binding motif (S/TXV) at their carboxy termini, and yeast two hybrid analyses established that the PTEN phosphatase binds to PDZ domains of a family of membrane associated guanylate kinases (MAGUKs), peripheral membrane associated proteins with multiple protein interaction domains which function to juxtapose signaling molecules and position them near the by guest on November 19, 2017 http://www.jbc.org/ Downloaded from 6 plasma membrane [23] . Interestingly, some tumor derived mutations are found at the extreme carboxy terminus of PTEN, and these mutations would be expected to disrupt PDZ domain binding interactions, consistent with an important functional role for PDZ domain binding in PTEN tumor suppression. Because these MAGUKs are localized specifically to intercellular tight junction regions, these studies also suggested mechanisms for the positioning of the PTEN phosphatase to the lipid domains of subcellular regions such as the epithelial tight junction, a site known to be involved with the regulation of cell survival [24] .
In this paper we describe a novel homologue of PTEN, termed PTEN 2, which has been identified using database searches. Interestingly, this novel phosphatase is expressed uniquely in testis, and specifically in the secondary spermatocytes. In contrast to PTEN, PTEN 2 contains several potential transmembrane domains, which appear to target the phosphatase to the golgi apparatus. Molecular modeling suggests that PTEN 2 is a lipid phosphatase with many active site residues conserved with PTEN, and enzymatic analysis demonstrates that the novel phosphatase actively dephosphorylates PIP 3,5 and PIP 3,4,5 in vitro. Together, these data suggest that PTEN 2 is a phospholipid phosphatase which may play a role in the terminal stages of spermatocyte maturation by regulating intracellular levels of phosphatidylinositol-3-phosphate phospholipids.
Materials and Methods
PTEN DNA constructs. An human EST related to PTEN was initially identified from searches of public and private databases. By using various protocols, including screening a testis cDNA library and PCR methods, we obtained a full-length sequence of human PTEN 2. A fragment of human PTEN 2 cDNA was used as a probe to isolate a full Phosphoinositide phosphatase assay. The lipid-based phosphatase reactions were performed essentially as described [25] . The reactions (50 µl) contained 100 mM Tris(pH8.0),10 mM dithiothreitol, 100 uM phosphatidyl inositol phosphate substrates, (Echelon), 1.0 mM phosphatidylserine (Avanti, #830052) and 50 ug/ml PTEN2 or 10 ug/ml PTEN. Reactions were run at 37 o C for 3 hours and centrifuged at 20,000g for 15 min. The supernatants were treated with malachite green (Biomol Green, # AK-111) and absorbance was measured at A650.
Results

Sequence characterization of a PTEN homologue. Perusal of human and murine
DNA sequence databases demonstrated a closely related homologue of PTEN in both species. Cloning of cDNAs encoding both the human and murine forms of the homologue revealed that, while a diversity of sequences were expressed in the human, a single species was found in the mouse. While this work was being completed, a human homologue of the murine sequence was reported, and chromosomal mapping suggested that there were a number of different PTEN-homologous genes encoded in the human genome, some of which appeared to be psuedogenes [26] . The sequence of the 664 amino acid (m.w. 76, 719 daltons) mouse protein is illustrated in figure 1 and compared with 10 the reported human PTEN 2 homologue and with PTEN. This figure illustrates that both the human and murine PTEN homologues are extended at their amino-termini, and hydropathy analysis (figure 1) reveals that, in contrast to PTEN, the murine and human homologues appear to contain four high-probability transmembrane domains followed by the catalytic domain. Interestingly, all four potential transmembrane domains contain charged residues embedded within the hydrophobic potential membrane-spanning sequence (figure 1). Using a structural algorithm , which predicts membrane topology (Dr. Thomas Wu-personnal communication), we find that the murine homologue of PTEN may have a membrane spanning structure, which is reminiscent of ion channels ( figure   1 ). This sequence analysis suggests that the murine and human PTEN homologues appear to have extended amino termini, which may be involved with intracellular membrane association. FISH mapping revealed that the murine homologue mapped to a single locus on chromosome 8 between A3 and A4 (data not shown).
The murine homologue appears to have a number of residues throughout the catalytic domain, which are conserved with PTEN (figure 1). Importantly, many of these residues are likely to be involved with substrate recognition and catalytic activity (figure 2) [12] . For example, residues D 426 , H 427 , C 458 , K 459 , G 461 , R 462 and Q 510 , which are identical between the two proteins, were all proposed to be involved with substrate recognition in the structural analysis of PTEN. In addition, figure 2 also illustrates that the vast majority of the tumor-associated PTEN mutations, many of which are known to disrupt catalytic activity, occur at residues that are also either identical or conserved between the PTEN and the PTEN homologue. These comparative data suggest that the murine and human homologues are likely to have similar substrate specificity as PTEN, and we have therefore termed the new protein PTEN 2.
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The structure of PTEN has been recently solved by X-ray crystallography at 2.1 angstroms resolution [12] . This analysis revealed a molecule consisting of an Nterminal phosphatase domain and a C-terminal C2 lipid binding motif which were tightly packing against each other through a large interface. The phosphatase active site is similar to that observed in protein tyrosine phosphatases, including the essential catalytic residues, but is enlarged to allow for the binding of the larger phosphoinositide substrate. C2 domains have been shown to mediate membrane lipid association. Based on the 39% sequence identity between PTEN2 and PTEN, a three dimensional model of the phosphatase and C2 domains of PTEN2 has been built by homology modeling and threading techniques using the PTEN structure as template (figure 2). The existence of a C2 domain in PTEN2 (PTEN2-C2) was established by using threading analysis and the high conservation of residues forming the phosphatase domain/C2 interface (figure 2). This domain presents a 23% sequence identity with the PTEN C2 domain (PTEN-C2). In In order to determine if the amino-terminal transmembrane-containing region was involved with golgi localization, truncated forms of the protein encoding either the N-terminal transmembrane motifs or the C-terminal phosphatase and C2 domains were also expressed in COS cells. Figure 5 reveals that the C-terminal fragment of the protein appeared as a diffusely stained signal throughout the cytoplasm and in the nucleus, while the amino terminal fragment containing the transmembrane motifs was found to colocalize with the perinuclear golgi apparatus in a manner that was similar to the full length protein, consistent with the suggestion that the subcellular localization of the protein is mediated by these hydrophobic domains. These results suggest that, in contrast to PTEN which appears to be cytoplasmically localized in transfected cells, PTEN 2 appears to be localized to the golgi apparatus via an interaction that is likely to be mediated by one or more of the amino-terminal transmembrane motifs.
Enzymatic activity of PTEN 2. Homology modeling (figure 2) strongly suggested that PTEN 2 might be a lipid phosphatase with specificity for the 3-phosphorylated phosphatidylinositols that are products of a PI3 kinase reaction. In order to examine the lipid phosphatase activity of PTEN 2, a truncated form of the protein including the catalytic region and the potential C2 domain was produced in and isolated from transfected mammalian cells. As a control, a truncated form of PTEN 2 with a mutation at the critical active site cysteine (Cys 458 Ala) was also produced. Full length wild type PTEN and active site mutated (Cys 124 Ala) were also produced as positive controls using the baculovirus system. Each of these isolated proteins was tested for dephosphorylation of a variety of phosphatidyl inositol substrates in an in vitro malachite green enzyme assay. Figure 6 illustrates that the wild type version of PTEN was able to release phosphate from a diversity of substrates, including those containing phosphate at the 3 position. This activity was completely abolished in the Cys 124 Ala active site mutant (data not shown). While this apparent lack of substrate specificity is at odds with the accepted activity of PTEN towards only the 3 phosphate position, it should be remembered that this assay is performed under artificial conditions in vitro. Importantly, the activity of the PTEN 2 phosphatase domain appeared to be directed towards substrates containing phosphates at both the 3 and 5 positions. Thus, while the enzyme showed strong activity against PIP 3,5 and PIP 3,4,5 substrates, there was lower activity against PIP 3 and PIP 3,4. Because molecular modeling predicts that this enzyme is a 3 phosphatase, together with the complete lack of homology between PTEN 2 and phosphatases with specificity for the 5 position of phosphatidyl inositols, we propose that PTEN 2 removes the 3 phosphate from the PIP 3,5 and PIP 3,4,5 substrates. However, further analysis of the structures of the dephosphorylated substrates will be required to delineate the exact specificity of this enzyme. In summary, as predicted from molecular modeling, PTEN 2 appears to be a lipid phosphatase with specificity for a subset of 3-phosphorylated phosphatidylinositols.
Discussion
The regulation of phosphatidyl inositol levels is a critical component of a diversity of cellular functions ranging from cell survival to membrane trafficking [1] .
The levels of these various phospholipids are determined by a number of factors including the activities of various lipid kinases and phosphatases. One lipid phosphatase, termed PTEN, is especially interesting because of its association with a survival 16 pathway in cells as well as its apparent tumor suppressor activity . Because PTEN is the first phosphatase, which appears to dephosphorylate phospholipids at the 3 position, the identification of other phosphatases with similar activity is of great interest. The data described here report a novel relative of PTEN, termed PTEN 2, which has many of the enzymatic characteristics of PTEN, but which shows significant differences with the original enzyme, including a unique cell-type specificity and an association with the golgi secretory compartment.
The three-dimensional structure of PTEN provided a number of insights into the potential mechanisms by which this phosphatases recognizes and dephosphorylates its 3-phosphate-containing phospholipid substrates [12] . Because of the high degree of sequence homology between PTEN and the novel PTEN 2 described here, we were able to produce a model for the novel enzyme by homology modeling. This model predicted a number of interesting aspects about the novel enzyme. First the model suggested that the novel enzyme should have lipid phosphatase activity specific for the 3 position of the phospholipid, and this prediction was confirmed in our enzymatic assays. In addition, the model predicted that the novel phosphatase contains a C-terminal C2 domain which has the potential for interacting with membrane lipids. Perhaps more interesting is the conservation in the interface between the phosphatase and C2 domain in both PTEN and PTEN 2. This conservation suggests that this region may have functional importance, and analysis of tumor-derived mutations in this region of PTEN suggested that this interface is important for the maintenance of enzyme activity [12] . Interestingly, enzymatic analysis suggests that PTEN 2 has a greater degree of specificity for phospholipids containing phosphate at both the 3 and 5 positions. It will be important to examine the differences between the PTEN and PTEN 2 phosphatase domains to determine the mechanism by which this specificity is attained. The current model of PTEN 2, together In summary, the results reported here suggest that a closely related homologue of PTEN, termed PTEN 2, appears to be a golgi-associated lipid phosphatase, which is expressed, in the terminal stages of sperm development. While the exact function of this 19 phosphatase remains to be determined, the data suggest a potential role in membrane trafficking regulated by the golgi apparatus. It will be of significant interest to produce mice that are null mutants of this enzyme to determine its role in spermatogenesis, and we are currently analyzing mice with mutations in this phosphatase. In addition, further studies into the exact specificity of the phosphatase in vivo, as well as the effects of the expression of this enzyme on vesicular trafficking, should provide insights into its function. Finally, the mechanisms by which this phosphatase specifically degrades 3,5-containing phospholipids will require a further understanding of the structure- 
